TPPs & TPCs

We help companies to develop target product profiles and target product claims to ensure that medicines deliver meaningful benefit to patients and value to payers, at time of launch

Robust research to
inform TPPs/ TPCs

Developing a robust Target Product Profile (TPP) for an asset in early development is one of the most important undertakings to ensure commercial success. Oncology Access Solutions Ltd has considerable experience in developing TPPs for cancer medicines and validating these with payers and patient advocacy groups (PAGs). Target Product Claims (TPCs) are key to informing what evidence needs to be captured from clinical and RWE studies to substantiate regulatory labelling claims.

$375bnexpected spending total on cancer medicines by 2027

5%global increase number of treated patients over the past five years

2,000oncology products currently under development

a consultancy you can trust

we are  
industry experts

we are
dedicated

we are
patient-centric

a wealth of life science
knowledge and expertise

Oncology Access Solutions Ltd is led and founded by Dr Clare Hague – a highly experienced health economist and health services researcher with a strong industry and academic background.

With over 18 years of industry experience with large, mid-sized and start-up biotech companies, we Clare is a seasoned and knowledgeable independent consultant able to provide a discreet and dedicated service.

Learn more